NO20085098L - Behandling av ischemisks sykdommer ved bruk av erytropoietin - Google Patents

Behandling av ischemisks sykdommer ved bruk av erytropoietin

Info

Publication number
NO20085098L
NO20085098L NO20085098A NO20085098A NO20085098L NO 20085098 L NO20085098 L NO 20085098L NO 20085098 A NO20085098 A NO 20085098A NO 20085098 A NO20085098 A NO 20085098A NO 20085098 L NO20085098 L NO 20085098L
Authority
NO
Norway
Prior art keywords
subject
erythropoietin
treatment
peripheral blood
ischemic diseases
Prior art date
Application number
NO20085098A
Other languages
English (en)
Norwegian (no)
Inventor
Toshio Matsumoto
Tetsuya Kitagawa
Masahiro Abe
Masashi Akaike
Kazunari Nagayoshi
Kaname Yamamoto
Masato Higuchi
Original Assignee
Univ Tokushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokushima filed Critical Univ Tokushima
Publication of NO20085098L publication Critical patent/NO20085098L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20085098A 2006-06-07 2008-12-08 Behandling av ischemisks sykdommer ved bruk av erytropoietin NO20085098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006158998 2006-06-07
PCT/JP2007/061525 WO2007142288A1 (ja) 2006-06-07 2007-06-07 エリスロポエチンを用いた虚血性疾患の治療

Publications (1)

Publication Number Publication Date
NO20085098L true NO20085098L (no) 2009-02-27

Family

ID=38801534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085098A NO20085098L (no) 2006-06-07 2008-12-08 Behandling av ischemisks sykdommer ved bruk av erytropoietin

Country Status (16)

Country Link
US (1) US20090280094A1 (pt)
EP (1) EP2047859A4 (pt)
JP (2) JP5326079B2 (pt)
KR (1) KR20090031547A (pt)
CN (1) CN101460188B (pt)
AR (1) AR061269A1 (pt)
AU (1) AU2007255717B2 (pt)
BR (1) BRPI0712063A2 (pt)
CA (1) CA2654154A1 (pt)
IL (1) IL195648A0 (pt)
MX (1) MX2008015392A (pt)
NO (1) NO20085098L (pt)
NZ (1) NZ573792A (pt)
RU (1) RU2008152746A (pt)
TW (1) TW200815026A (pt)
WO (1) WO2007142288A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007255717B2 (en) * 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin
CA2952805C (en) 2009-06-05 2021-06-01 Cellular Dynamics International, Inc. Reprogramming t cells and hematopoietic cells
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations
CN101940590B (zh) * 2010-08-27 2013-09-18 上海士腾生物技术有限公司 促进创伤愈合的制剂及其制备方法
CN101940594B (zh) * 2010-08-27 2013-12-04 上海士腾生物技术有限公司 用于治疗缺血性心血管疾病的制剂及其制备方法
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
EP3006561B1 (en) * 2013-06-05 2019-12-04 Seoul National University R&DB Foundation Peripheral blood stem cells with improved angiogenic properties and use thereof
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501010A (ja) 1984-12-04 1987-04-23 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド エリトロポエチンの生産方法
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
AU646822B2 (en) 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
CN1764470A (zh) * 2003-03-27 2006-04-26 詹森药业有限公司 促红细胞生成素在中风康复中的用途
WO2004087063A2 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
JP2006158998A (ja) 2004-12-02 2006-06-22 Nippon Sheet Glass Co Ltd ロッドの反り選別装置
HUE035655T2 (en) * 2005-08-05 2018-05-28 Araim Pharmaceuticals Inc Tissue protective peptides and their use
AU2007255717B2 (en) * 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin

Also Published As

Publication number Publication date
EP2047859A1 (en) 2009-04-15
BRPI0712063A2 (pt) 2011-12-20
JP2013116919A (ja) 2013-06-13
CA2654154A1 (en) 2007-12-13
AR061269A1 (es) 2008-08-13
MX2008015392A (es) 2009-05-05
CN101460188A (zh) 2009-06-17
EP2047859A4 (en) 2010-05-05
KR20090031547A (ko) 2009-03-26
US20090280094A1 (en) 2009-11-12
IL195648A0 (en) 2011-08-01
HK1128419A1 (en) 2009-10-30
JP5326079B2 (ja) 2013-10-30
JPWO2007142288A1 (ja) 2009-10-29
AU2007255717A1 (en) 2007-12-13
CN101460188B (zh) 2013-09-04
RU2008152746A (ru) 2010-07-20
WO2007142288A1 (ja) 2007-12-13
AU2007255717B2 (en) 2013-07-11
TW200815026A (en) 2008-04-01
NZ573792A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
Kelters et al. Circadian rhythms in cardiovascular disease
Slegtenhorst et al. Mechanisms and consequences of injury and repair in older organ transplants
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
Kiuchi et al. New approaches in the management of sudden cardiac death in patients with heart failure—targeting the sympathetic nervous system
El-Bassossy et al. Cardioprotection by 6-gingerol in diabetic rats
Zhou et al. Effects of various degrees of oxidative stress induced by intermittent hypoxia in rat myocardial tissues
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
MX2008015392A (es) Tratamiento de enfermedades isquemicas que usan eritropoyetina.
Wang et al. The role of renin-angiotensin system in cellular differentiation: implications in pancreatic islet cell development and islet transplantation
Grace et al. Proposed mechanism for increased COVID-19 mortality in patients with decompensated cirrhosis
Calò et al. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications
Waheed et al. The role of hyperuricemia in the progression of end‐stage kidney disease and its molecular prospective in inflammation and cardiovascular diseases: A general review
Xing et al. The effects of allitridi and amiodarone on the conduction system and reverse use-dependence in the isolated hearts of rats with myocardial infarction
WO2008011134A3 (en) Use of late passage mesenchymal stem cells (mscs) for treatment of cardiac rhythm disorders
WO2008081447A3 (en) Compounds and methods for detection of cells
Lee et al. Lack of modulatory effect of simvastatin on indoxyl sulfate-induced activation of cultured endothelial cells
Liang et al. Human Induced Pluripotent Stem Cells in Cardiovascular Disease: Mechanisms and Translational Applications
Austruy et al. Are there specific prognostic factors for acute coronary syndrome in patients over 80 years of age?
Dhanasekaran et al. Glyburide, a K+ ATP channel blocker, improves hypotension and survival in anaphylactic shock induced in Wistar rats sensitized to ovalbumin
WO2009149931A3 (en) Fatty acid binding protein in the pathogenesis of cardiac dysfunction
Zhang et al. Temporal gene expression profiling reveals the protective mechanism of APIP in atrial fibrillation following myocardial infarction
WANG et al. Phenotypic study on human high-altitude acclimatization
Wang et al. Comparative Exosomal microRNA Expression Profiles From Patients of Pulmonary Arterial Hypertension With Human Umbilical Mesenchymal Stem Cells Treatment
Reverentia et al. Effect of Short-Acting Loop Diuretics on 24-hour Heart Rate Variability and Blood Pressure in Patients with Acute Decompensated Heart Failure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application